Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 4,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Integrated HIV Prevention and HCV Care for PWID

NCT03981445
View directory record Official record
Conditions
HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions
ARTAS Adapted Patient Navigation, Adherence Counseling
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

NCT04349072
View directory record Official record
Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

NCT02919475
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Tucson, Arizona • Upland, California • Clearwater, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Coordinating Center for Enhancing ADRD Caregiving

NCT00178165
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Skill Training Condition - problem solving training, REACH for TLC (Telephone Linked Computer) system
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
5
States / cities
Birmingham, Alabama • Menlo Park, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients

NCT03377803
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

NCT05188261
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional

A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders

NCT01116388
View directory record Official record
Conditions
Autism, Gastrointestinal Symptoms
Interventions
GFCF product with GFCF diet, product containing gluten and casein (milk protein) with GFCF diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 31, 2026, 6:51 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Strengthening Families Program Online

NCT04214327
View directory record Official record
Conditions
Substance Abuse
Interventions
Strengthening Families Program Online eLearning Game, SFP Home-use DVD, Wait-Listed Control
Behavioral
Lead sponsor
Strengthening Families Program LLC
Industry
Eligibility
11 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827
View directory record Official record
Conditions
Kidney Disease
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 31, 2026, 6:51 AM EDT
Recruiting Phase 2 Interventional

Preventing Injured Knees From osteoArthritis: Severity Outcomes

NCT06096259
View directory record Official record
Conditions
Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions
Metformin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional

A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain

NCT07767669
View directory record Official record
Conditions
Arthritis, Joint Pain, Muscle Pain, Musculoskeletal Pain, Joint Stiffness
Interventions
Intervention (Saje Pain Release Joint & Arthritis Cream), Placebo Comparator
Dietary Supplement
Lead sponsor
Saie Beauty
Industry
Eligibility
20 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

NCT00950807
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo, GSK573179
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 31, 2026, 6:51 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259334
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Lancaster, California • Rialto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency

NCT00355264
View directory record Official record
Conditions
Tetrahydrobiopterin Deficiencies, Hyperphenylalaninemia, Non-Phenylketonuric
Interventions
Phenoptin
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

NCT01306422
View directory record Official record
Conditions
Appetite Depressant, Overweight, Body Weight
Interventions
Hoodia gordonii purified extract (H.g.PE), Placebo yogurt drink
Other
Lead sponsor
Unilever R&D
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder

NCT01766401
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazadone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Arcadia, California • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

NCT01518972
View directory record Official record
Conditions
Alcohol Abuse, Posttraumatic Stress Disorder
Interventions
Prazosin, Placebo medication
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 31, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

NCT02197130
View directory record Official record
Conditions
Huntington's Disease
Interventions
PF-02545920, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 31, 2026, 6:51 AM EDT